Factor IX Alteration P.arg338gln (FIX Shanghai) Potentiates FIX Clotting Activity and Causes Thrombosis
Wenman Wu,Lin Xiao,Xi Wu,Xiaoling Xie,Ping Li,Changming Chen,Zhe Zheng,Jiangang Ai,Alexander Valencia,Birong Dong,Qiulan Ding,Biao Dong,Xuefeng Wang
DOI: https://doi.org/10.3324/haematol.2019.216713
2020-01-01
Haematologica
Abstract:Hemophilia B is almost exclusively caused by mutations of the F9 gene and inherited in an X-linked recessive manner. The amino acid residue arginine of factor IX (FIX) with CpG sequences is a hot spot for mutations, involving CG to TG or CA transitions and causing hemophilia B. Interestingly, for the coding sequence of residue Arg338 of FIX, only the transition CGA to TGA, which causes nonsense mutations, had been identified in a patient with severe hemophilia B, whereas the other type of CpG transition predicting the missense mutation p.Arg338Gln has been strangely absent from the list of F9 mutations reported in the hemophilia B database. It had been suspected that the particular type of amino acid replacement at this site may lead to conditions other than hemophilia. In a Chinese patient with deep vein thrombosis (DVT), we identified a F9mutation at the same site as that in FIX Padua, but differently from this latter, the arginine is changed to a polar amino acid residue glutamine (p.Arg384Gln, HGVS numbering; or p.Arg338Gln, legacy numbering) due to the nucleotide transition c.1151G>A. A coagulation function assay with both the patient’s plasma and recombinant FIX p.Arg338Gln (p.R338Q) showed that the mutation also increased FIX activity. When the FIX with the p.R338Q modification was expressed in vivo after being transferred with self-complementary adeno-associated virus (scAAV) vectors, the deficiency of FIX in a mouse model of hemophilia B was restored, and the bleeding phenotype was significantly ameliorated. A 13-year old boy was referred to Ruijin Hospital for consultation regarding recurrent DVT. The patient was well and had no history of other major disorders. The two episodes of DVT had affected both femoral and popliteal veins of his left leg and the diagnosis was confirmed by ultrasound studies. He had no history of left leg trauma and no vascular abnormality was identified in the imaging study. There was no confirmed family history of venous thromboembolism. The patient was being treated with warfarin and this had not been discontinued during the study because of the potential risk of DVT recurrence. The study was approved by the ethics committee of Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine. Written consent was acquired from family members and the patient’s mother on behalf of both parents. Under treatment with warfarin, the activity of three other K-dependent coagulation factors, factors II, VII and X, was significantly suppressed in the patient; however, his plasma maintained highly elevated FIX activity (FIX:C around 143.1% of normal). In addition, the plasma FIX antigen (FIX:Ag) level was much lower, at approximately 27.5% of normal. The patient’s mother also had relatively higher FIX clotting activity (FIX:C 155.3%) and her FIX:Ag was 75.8% of normal (Table 1). Thus, the ratios between FIX:C and FIX:Ag were significantly higher for both the patient and his mother, being 5.20 and 2.06, respectively. The antithrombin III (AT III) level was within the normal range and lupus anticoagulant and antiphospholipid antibodies were negative in both the patient and his mother. Although we were unable to determine the patient’s protein C (PC) and protein S (PS) levels accurately, because of his treatment with warfarin, the levels of PC and PS were both within normal ranges in the mother (data not shown). The patient’s father was not available for analysis. The coding sequence and flanking regions of the F9 gene were amplified by polymerase chain reaction and directly sequenced. The genes coding for PS, PC, AT III and common genetic thrombotic risk factors, including the factor V Leiden mutation and prothrombin G20210G/A, were screened. Direct sequencing of the F9 gene revealed a nucleotide substitution c.1151G>A (Figure 1A), which predicated a missense mutation p.Arg338Gln (p.R338Q). The genetic variant was traced back to the patient’s mother (Figure 1B). This pedigree was negative for both factor V Leiden and the prothrombin G20210A mutation. Analysis of the genes for PS, PC and AT III failed to reveal any pathogenic changes (data not shown). The F9 cDNA containing the p.R338Q mutation were inserted into the mammalian expression vector pCDNA3.1 and transfected into HEK293T cells using lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA) to produce FIX (the methods are described in the Online Supplementary File). The amount and coagulation activity of FIX were determined by enzyme-linked immunosorbent assay and an activated partial thromboplastin time-based clotting assay. Recombinant FIX was subjected to sodium dodecylsulfate polyacrylamide gel electrophoresis and detected by western blotting using a FIX-specific antibody (PAHFIX-S, Haematologic Technologies, Essex Junction, VT, USA). As shown in Figure 1C, the recombinant FIX Shanghai had a similar migration pattern as that of the wild-type FIX and the mutation increased the FIX activity by approximately 5fold as determined by the ratio of FIX:C to FIX:Ag (Figure 1D), which was similar to the change of FIX activity observed in the patient. We further investigated the expression and function of FIX p.R338Q in a murine model of hemophilia B using both high and low doses of recombinant adeno-associated virus (rAAV) vectors, with wild-type FIX and FIX p.R338L. The plasmid scAAV-TTR-hFIXco (AAV-hFIXco) was constructed by cloning codon-optimized human FIX (hFIXco) cDNA under the control of the human transthyretin (TTR) promoter in a scAAV vector plasmid, and with two inverted terminal repeat sequences of AAV2 flanking the human FIX gene expression cassettes.